N- (3- (1H- benzimidazol- 2- yl)- 4- chlorophenyl)pyridine- 3- carboxamide

activates potassium channel Kv11.1; structure in first source

Also Known As:

AZSMO-23

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Long QT Syndrome 06/01/2015 - "The activity of AZSMO-23 and those of its close analogues suggest these compounds may be of value to elucidate the mechanism of type 2 hERG activators to better understand the pharmacology of this area from both a safety perspective and in relation to treatment of congenital long QT syndrome."